Drug Discovery

Trial compared QIV with trivalent vaccines in children aged 6 months to 8 years.

The company’s platform is designed to activate immune responses against cancer and infectious diseases.

Scientists have used modified strains of Zika virus to kill glioblastoma stem cells in cancer-bearing mice, and prolong their lifespan

CUT&RUN and CUT&Tag assays are dramatically changing how scientists perform chromatin mapping experiments by providing high-quality data using low cell inputs and sequencing depths. Some have speculated that these novel strategies will render the standard ChIP-seq assay obsolete in the next decade. The result of CUT&RUN and CUT&Tag assays, enabled by EpiCypher’s CUTANA™ platform, is highly efficient and streamlined isolation of target fragments for ultra-sensitive chromatin mapping.

Contrary to generally held belief, most essential oil components are amenable to medicinal chemistry techniques and may qualify as good drug candidates, report scientists based at VIB-KU Leuven. Moreover, these components also offer attractive opportunities for lead optimization or even fragment-based drug discovery. Because their therapeutic potential is still under-scrutinized, the scientists propose that essential oil components be explored more vigorously with present-day methods.

MIT engineers have now developed a tissue model that mimics beta-amyloid's effects on the blood-brain barrier, and used it to show that this damage can lead molecules such as thrombin, a clotting factor normally found in the bloodstream, to enter the brain and cause additional damage to Alzheimer's neurons.

Pfizer is partially funding OPKO Health’s hGH-CTP development and commercialization initiatives in a deal that is potentially worth more than $570 million.

Nanoparticle vaccine stabilizes headless stalks, protects mice against divergent flu viruses

Philadelphia-based Passage Bio develops gene therapies for rare, monogenic CNS disorders through a strategic collaboration and licensing agreement with the University of Pennsylvania’s Gene Therapy Program (GTP) to conduct discovery and IND-enabling preclinical work. A year after it was launched in 2019, the company went public through an initial public offering that raised $227.5 million. Passage Bio’s co-founders include GTP Director and gene therapy pioneer James M. Wilson, MD, PhD.

Researchers have identified a new mechanism for targeting an important cancer gene.